Stephens lowered the firm’s price target on Definitive Healthcare (DH) to $2 from $3 and keeps an Equal Weight rating on the shares. Turnaround efforts should drive Life Sciences revenue back to growth, but the firm sees the timing as uncertain, the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DH:
- Definitive Healthcare price target lowered to $2 from $3 at Stephens
- Definitive Healthcare price target lowered to $3 from $4 at Canaccord
- Definitive Healthcare reports Q4 adjusted EPS 6c, consensus 6c
- Definitive Healthcare sees Q1 adjusted EPS 3c, consensus 6c
- Definitive Healthcare sees FY26 adjusted EPS 14c-17c, consensus 26c